BioNxt Solutions (OTCMKTS:BNXTF) (OTCMKTS:BNXTF) is a life sciences company specializing in advanced proteomics, metabolomics and bioinformatics solutions. The company’s platform combines state-of-the-art mass spectrometry and chromatography workflows with cloud-based data analysis tools, enabling high-throughput characterization of proteins, metabolites and other biomolecules for research and development purposes.
BioNxt Solutions offers contract research services to clients in the pharmaceutical, biotechnology and academic sectors, providing end-to-end support from sample preparation through to data interpretation. Its services include quantitative proteomic profiling, metabolomic screening, post-translational modification mapping and custom assay development. By integrating proprietary protocols with machine learning algorithms, the company aims to accelerate target discovery, biomarker identification and drug development projects.
Headquartered in Vancouver, British Columbia, BioNxt Solutions serves customers across North America, Europe and Asia, supporting projects in areas such as oncology, neurology and infectious disease research. The company’s multidisciplinary leadership team brings together expertise in analytical chemistry, computational biology and commercial operations to drive growth and innovation in the rapidly evolving omics market.
Committed to expanding its global footprint, BioNxt Solutions continues to invest in research and development, strategic partnerships and infrastructure enhancements. The company’s long-term strategy focuses on advancing precision medicine by delivering scalable, high-resolution analytical platforms and data-driven insights that meet the complex needs of modern life science and healthcare industries.
